查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1986453

肺動脈高壓治療市場報告：按藥物類別、給藥途徑、最終用戶和地區分類（2026-2034 年）

Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球肺動脈高壓（PAH）治療市場規模達84億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到121億美元，2026年至2034年的複合年成長率（CAGR）為4.05%。該市場正經歷顯著成長，主要得益於標靶治療的進步、PAH盛行率的上升以及公眾意識的提高。不斷擴大的研發投入也為全球市場帶來了更光明的前景。

肺動脈高壓治療市場趨勢：

擴大聯合治療的應用

為了提高肺動脈高壓 (PAH) 的治療效果，醫生們擴大採用聯合治療。透過合併使用不同治療類別的藥物，他們能夠針對治療 PAH 涉及的多個生物學路徑。這種多管齊下的方法有助於更有效地控制症狀、延緩疾病進展並改善患者的整體預後。此外，聯合治療還可以降低單一藥物的劑量，從而可能減少副作用並提高患者的依從性。隨著臨床證據支持其有效性，聯合治療正逐漸成為 PAH 治療的標準療法，推動市場成長和創新。例如，2024 年 3 月，強生公司的 OPSYNVI®（Macitentan和他達拉非）成為首個獲得美國 FDA核准的用於治療成人肺動脈高壓 (PAH) 的每日一次單片複方製劑。該核准基於 III 期 A 類藥物評估試驗 (DUE) 的成功，該試驗證實了肺血流動力學的顯著改善。 OPSYNVI(R) 將兩種成熟的治療方法結合到一片藥片中，符合建議早期聯合治療的臨床指引。

人們越來越重視創新治療方法。

隨著人們對肺動脈高壓 (PAH) 創新治療方法的興趣日益濃厚，旨在解決該疾病根本原因的基因療法和生物目標的研究正在取得進展。基因療法有望改變 PAH 相關的遺傳因素，從而提供超越單純症狀管理的長期解決方案。另一方面，生物目標則專注於導致疾病進展的特定分子通路，從而實現更個人化和有效的治療。這些新方法代表了緩解疾病的突破，並有望提高 PAH 患者的存活率和整體生活品質。因此，Liquidia 公司的 YUTREPIA™（曲前列尼爾）吸入粉劑於 2024 年 8 月獲得美國食品藥物管理局 (FDA) 的臨時批准，用於治療成人肺動脈高壓 (PAH) 和伴有間質性肺病 (ILD) 的肺動脈高壓 (PH-ILD) 患者。此次核准是基於食品藥物管理局 III 期臨床試驗，該試驗證實了 YUTREPIA 的安全性和有效性。該公司計劃盡快尋求最終核准，以滿足 PAH 和 PH-ILD 患者未被滿足的醫療需求。

以病人為中心的照護和數位健康

以患者為中心的護理措施和數位健康工具的整合正在透過提高治療依從性和療效，影響肺動脈高壓 (PAH) 治療市場的動態。行動應用程式和穿戴式裝置等數位健康工具能夠持續監測心率和血氧飽和度等生命徵象。此外，數位平台促進了患者與醫療團隊之間的順暢溝通，從而改善了疾病的整體管理。這種整合不僅改善了患者的治療效果，還使患者能夠在自身的 PAH 管理中發揮積極作用，從而提高生活品質並提升醫療服務的效率。此外，2024 年發表在《美國醫學傳播雜誌》(AJMC) 上的報導指出，孿生技術有望徹底改變肺動脈高壓 (PH) 的治療方式。該技術透過創建患者的虛擬模型來模擬疾病進展並預測治療結果。這項研究凸顯了個人化醫療和In Silico臨床試驗的潛力，它們可以減少傳統臨床試驗所需的時間和成本。數位健康和​​孿生技術的這些進步正在改善肺動脈高壓治療市場的前景，推動市場成長，並有助於改善患者照護。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：肺動脈高壓（PAH）治療的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類別分類

  • 內皮素受體拮抗劑（ERA）
  • 血管擴張劑
  • 磷酸二酯酶 5 (PDE-5) 抑制劑
  • 可溶性鳥苷酸環化酶（sGC）促效劑
  • 鈣離子通道阻斷劑（CCBs）
  • 前列腺環素和前列腺環素類似物
  • 其他

第7章 市場區隔：依給藥途徑

  • 吸入
  • 注射藥物
  • 口服

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 診所
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Actelion Pharmaceuticals Ltd（Johnson & Johnson）
    • Arena Pharmaceuticals Inc.
    • AstraZeneca PLC
    • Bayer Aktiengesellschaft
    • Daiichi Sankyo Company Limited
    • Gilead Science Inc.
    • GlaxoSmithKline PLC
    • Merck KGaA
    • Novartis International AG
    • Pfizer Inc.
    • United Therapeutics Corporation
Product Code: SR112026A2399

The global pulmonary arterial hypertension (PAH) drugs market size reached USD 8.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 12.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.05% during 2026-2034. The market is experiencing significant growth mainly driven by advancements in targeted therapies, increasing prevalence of PAH and growing awareness. Expanding research and development (R&D) efforts are also creating a positive outlook for the market further across the world.

PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET ANALYSIS:

  • Major Market Drivers: Key market drivers include the rising prevalence of PAH due to genetic factors and associated conditions such as cardiovascular diseases and HIV. Advancements in treatment options including novel therapies like endothelin receptor antagonists and prostacyclin analogs are boosting demand. An increased awareness among healthcare professionals and patients about early diagnosis and treatment also supports market growth. Moreover, supportive government initiatives and favorable reimbursement policies are encouraging greater accessibility to PAH medications. Ongoing research and development (R&D) to discover more effective therapies further drives the market growth, enhancing treatment options for patients worldwide.
  • Key Market Trends: Key market trends include a growing focus on combination therapies which offer enhanced efficacy by targeting multiple pathways involved in PAH. The rise of precision medicine is also influencing the market growth as personalized treatments are increasingly tailored to individual patient needs. There is also a noticeable shift toward oral and inhaled formulations, providing more convenience and better patient adherence as compared to intravenous options. Additionally, biotech companies are investing heavily in gene and cell-based therapies, which have the potential to revolutionize PAH treatment.
  • Geographical Trends: Geographical trends in market shows significant growth in North America, due to its advanced healthcare infrastructure, strong R&D investment, and higher PAH prevalence. Europe follows closely, with countries like Germany and the United Kingdom contributing through increased awareness and availability of advanced treatments. The Asia-Pacific region is experiencing rapid growth due to rising healthcare expenditure, improving diagnostic facilities, and growing awareness about PAH. In countries like China and India, expanding patient population base and increasing access to healthcare are fueling the demand for PAH drugs.
  • Competitive Landscape: Some of the major market players in the pulmonary arterial hypertension (PAH) drugs industry include Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation, among many others.
  • Challenges and Opportunities: The market faces various challenges including high treatment costs which can limit access especially in developing regions. The complexity of PAH as a disease, with its multiple pathways, also makes treatment development difficult. Limited awareness in certain regions further hampers early diagnosis and intervention. However, opportunities are emerging through advancements in gene and cell-based therapies, which have the potential to offer more effective treatments. Increased focus on combination therapies presents another growth avenue, improving patient outcomes. In line with this, improving healthcare access in developing regions offers significant market potential for PAH drug manufacturers.

PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET TRENDS:

Increased Use of Combination Therapies

Physicians are increasingly adopting combination therapies to enhance treatment efficacy in Pulmonary Arterial Hypertension (PAH). By prescribing a mix of drugs from different therapeutic classes, they target multiple biological pathways involved in PAH. This multifaceted approach helps to manage symptoms, slow disease progression, and improve overall patient outcomes more effectively. Additionally, combination therapies can allow for lower doses of individual medications, potentially reducing side effects and enhancing patient adherence. As clinical evidence supports their benefits, combination treatments are becoming the standard of care in PAH management, driving market growth and innovation. For instance, in March 2024, Johnson & Johnson's OPSYNVI(R) (macitentan and tadalafil) was approved by the U.S. FDA as the first once-daily single-tablet combination therapy for adults with pulmonary arterial hypertension (PAH). This approval is based on the successful Phase 3 A DUE study, which showed significant pulmonary hemodynamic improvement. OPSYNVI(R) combines two established treatments into a single tablet, aligning with clinical guideline recommendations for early combination therapy.

Rising Focus on Innovative Therapies

The rising focus on innovative therapies in Pulmonary Arterial Hypertension (PAH) is driving the exploration of gene therapies and targeted biologics, which aim to address the root causes of the disease. Gene therapies hold the potential to modify genetic factors involved in PAH, offering a long-term solution rather than just symptom management. Targeted biologics, on the other hand, focus on specific molecular pathways contributing to disease progression, allowing for more personalized and effective treatments. These novel approaches could lead to significant breakthroughs in disease modification, improving survival rates and overall quality of life for PAH patients. In line with this, in August 2024, Liquidia Corporation's YUTREPIA(TM) (treprostinil) inhalation powder received tentative approval from the U.S. FDA to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval is based on the Phase 3 INSPIRE trial, which demonstrated the safety and efficacy of YUTREPIA. The company plans to seek final approval at the earliest to address the unmet needs of PAH and PH-ILD patients.

Patient-Centered Care and Digital Health

Patient-centered care initiatives and the integration of digital health tools are influencing the pulmonary arterial hypertension drugs market dynamics by enhancing treatment adherence and outcomes. Digital health tools, including mobile apps and wearable devices, enable continuous monitoring of vital signs such as heart rate and oxygen levels. Additionally, digital platforms facilitate seamless communication between patients and medical teams, enhancing overall disease management. This integration not only improves patient outcomes but also empowers individuals to take an active role in managing their PAH, leading to increased quality of life and more efficient healthcare delivery. Moreover, in an article published by AJMC in 2024, it was suggested that twin technology has the potential to revolutionize pulmonary hypertension (PH) treatment. This technology involves creating virtual models of patients to simulate disease progression and predict treatment outcomes. The study emphasizes the potential for personalized care and in silico clinical trials, which could reduce the time and costs associated with traditional trials. These advancements in digital health and twin technology are creating a positive pulmonary arterial hypertension drugs market outlook, driving growth and improving patient care.

PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET SEGMENTATION:

Breakup by Drug Class:

  • Endothelin Receptor Antagonists (ERAs)
  • Vasodilators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
  • Calcium Channel Blockers (CCBs)
  • Prostacyclin and Prostacyclin Analogs
  • Others

Prostacyclin and Prostacyclin Analogs accounts for the majority of the market share

Prostacyclin and prostacyclin analogs dominate the pulmonary arterial hypertension (PAH) drugs market, accounting for the largest market share due to their critical role in managing the disease. These medications work by dilating blood vessels, reducing vascular resistance, and inhibiting platelet aggregation, which effectively lowers blood pressure in the pulmonary arteries. Their proven efficacy in improving exercise capacity and delaying disease progression makes them a cornerstone of PAH therapy. Additionally, the availability of various administration forms, such as intravenous, subcutaneous, and inhaled options, enhances their accessibility and convenience for patients. Ongoing advancements and the introduction of newer analogs further solidify their leading position, driving sustained pulmonary arterial hypertension drugs market growth .

Breakup by Route of Administration:

  • Inhalation
  • Injectable
  • Oral Administration

Oral Administration holds the largest share of the industry

Oral administration holds the largest share of the pulmonary arterial hypertension (PAH) drugs market due to its significant advantages in patient convenience and adherence. Oral medications are easy to administer, non-invasive, and can be taken at home without the need for specialized medical facilities, making them highly attractive for long-term treatment. This ease of use enhances patient compliance, which is crucial for managing a chronic condition like PAH. Additionally, advancements in pharmaceutical formulations have improved the efficacy and safety profiles of oral PAH drugs, thereby reducing side effects and increasing their appeal. For instance, in December 2023, Granules obtained approval from the U.S. Food and Drug Administration for its generic version of Viatris Specialty's Revatio, a treatment for pulmonary arterial hypertension (PAH). The product is bioequivalent and therapeutically equivalent to Viatris's Sildenafil for oral suspension, 10 mg/ml. Granules stated that the drug is intended to enhance exercise ability and delay clinical worsening in PAH patients.

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Hospitals are a primary end user in the Pulmonary Arterial Hypertension (PAH) drugs market, playing a crucial role in diagnosis, treatment, and ongoing management of the condition. Equipped with advanced diagnostic tools and specialized cardiology and pulmonology departments, hospitals facilitate the accurate identification of PAH, enabling timely and effective intervention. They administer a wide range of PAH medications, including advanced biologics and combination therapies, ensuring comprehensive patient care. Additionally, hospitals often participate in clinical trials and research initiatives, driving innovation and the development of new treatments. The centralized infrastructure and multidisciplinary approach in hospitals significantly contribute to the growth and adoption of PAH drugs in the market.

Clinics are essential end users in the Pulmonary Arterial Hypertension (PAH) drugs market, providing accessible and continuous care for patients with PAH. These outpatient facilities offer routine monitoring, medication management, and personalized treatment plans, enhancing patient adherence and outcomes. Clinics often collaborate with specialists to deliver comprehensive care, utilizing a variety of PAH drugs, including oral therapies and injectable medications. The convenience and localized presence of clinics make them pivotal in managing chronic conditions like PAH, ensuring that patients receive timely adjustments to their treatment regimens. Additionally, clinics contribute to market growth by increasing the distribution channels for PAH medications and fostering patient education and support initiatives.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest pulmonary arterial hypertension drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pulmonary arterial hypertension (PAH) drugs.

North America leads the Pulmonary Arterial Hypertension (PAH) drugs market, accounting for the largest market share due to several key factors. The region benefits from a highly advanced healthcare infrastructure and widespread access to specialized medical facilities, enabling effective diagnosis and treatment of PAH. According to pulmonary arterial hypertension drugs market overview, the rising prevalence of cardiovascular and respiratory diseases drives the demand for PAH medications across the region. Additionally, North America is home to major pharmaceutical companies that invest heavily in research and development (R&D), fostering innovation and the introduction of new therapies. Favorable regulatory frameworks and substantial healthcare funding further support market growth. Moreover, increased awareness and education about PAH contribute to the early detection and higher treatment rates, solidifying North America's dominant market position. For instance, in September 2023, researchers at Vanderbilt University developed a new drug, VU6047534, to treat pulmonary arterial hypertension without serious neurological side effects. The drug targets serotonin 2B receptors in the heart and lungs, promoting organ healing and potentially reversing damage from heart attacks. The compound, designed to stay out of the brain, represents a promising therapy for PAH. The research was funded by the National Institutes of Health and Vanderbilt University.

COMPETITIVE LANDSCAPE:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the pulmonary arterial hypertension (PAH) drugs industry include Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation. ()
  • The Pulmonary Arterial Hypertension (PAH) drugs market is highly competitive, with numerous pharmaceutical companies vying for market share through the development of innovative therapies. The market is characterized by a growing focus on advanced treatments, such as combination therapies and targeted biologics, which offer improved efficacy and patient outcomes. Companies are investing heavily in research and development to introduce novel drugs and enhance existing treatments. Pricing strategies, regulatory approvals, and patent expirations significantly influence market dynamics. Additionally, the increasing availability of generics intensifies competition, while market leaders leverage strong distribution networks and clinical trial results to maintain their positions.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global Pulmonary Arterial Hypertension (PAH) drugs market in 2025?

2. What is the expected growth rate of the global Pulmonary Arterial Hypertension (PAH) drugs market during 2026-2034?

3. What are the key factors driving the global Pulmonary Arterial Hypertension (PAH) drugs market?

4. What has been the impact of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) drugs market?

5. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the drug class?

6. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the route of administration?

7. What are the key regions in the global Pulmonary Arterial Hypertension (PAH) drugs market?

8. Who are the key players/companies in the global Pulmonary Arterial Hypertension (PAH) drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Endothelin Receptor Antagonists (ERAs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vasodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Soluble Guanylate Cyclase (sGC) Stimulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Calcium Channel Blockers (CCBs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Prostacyclin and Prostacyclin Analogs
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Inhalation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral Administration
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Arena Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca PLC
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bayer Aktiengesellschaft
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Daiichi Sankyo Company Limited
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Gilead Science Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 GlaxoSmithKline PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck KGaA
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis International AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 United Therapeutics Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pulmonary Arterial Hypertension Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 4: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Route of Administration (in %), 2025
  • Figure 5: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by End User (in %), 2025
  • Figure 6: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: North America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: North America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: United States: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: United States: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Canada: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Canada: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: China: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: China: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Japan: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Japan: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: India: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: India: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: South Korea: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: South Korea: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Australia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Australia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Indonesia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Indonesia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Europe: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Europe: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Germany: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Germany: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: France: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: France: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: United Kingdom: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: United Kingdom: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Italy: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Italy: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Spain: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Spain: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Russia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Russia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Latin America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Latin America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Brazil: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Brazil: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Mexico: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Mexico: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Global: Pulmonary Arterial Hypertension Drugs Industry: SWOT Analysis
  • Figure 83: Global: Pulmonary Arterial Hypertension Drugs Industry: Value Chain Analysis
  • Figure 84: Global: Pulmonary Arterial Hypertension Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pulmonary Arterial Hypertension Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 4: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Pulmonary Arterial Hypertension Drugs Market Structure
  • Table 7: Global: Pulmonary Arterial Hypertension Drugs Market: Key Players